Fig 1: Triptolide attenuated arthritis in DBA/1 mice model through targeting circ-0110634. (A-B) Cumulative incidence of arthritis and pathology severity score in DBA/1 mice with different treatments. (C) Circ-0110634 expression in injured joints from indicated groups of DBA/1 mice was measured by RT-qPCR. (D) The protein expression of TRAP, NFATc1 and CTSK in indicated mice joint tissues was measured by western blot analysis. **P ?< ?0.01.
Fig 2: Camk2d and Ppp3r2 are direct targets of miR-146a in vivo. (a-e) Immunohistochemical staining and quantitative analysis of the percentage of Camk2d, Ppp3r2, Nfatc1 and Nfatc2-positive chondrocytes in knee joint cartilage of 3- and 12-month-old WT or miR-146a KO mice. n=8 per group. Scale bars, 100 µm. (f-h) Immunohistochemical staining and quantitative analysis of the percentage of Camk2d and Ppp3r2-positive chondrocytes in knee joint cartilage harvested from the indicated groups. n=8–9 per group. Scale bars, 100 µm. Data are the mean±S.D. *P<0.05, **P<0.01 (Mann–Whitney test). NS, not significant between the indicated groups
Fig 3: NFATc1 (nuclear factor of activated T cell 1)/TRPC6 (transient receptor potential channel 6) contributed to high glucose (HG)-induced inflammation and apoptosis in HK-2 cells treated with tacrolimus (TAC). A, The expression of IL-6, fibronectin (FN), collagen 1 (Col-1) and cleaved caspase 3 (C-CAS3) in HK-2 cells incubated with TAC or NFATc1 siRNA and treated with or without the TRPC6 overexpression plasmid under HG conditions was detected by Western blot. A1-A3, Quantification of the average Western blot band intensity. B, C, The expression of NFATc1 and TRPC6 by real-time PCR. D, Western blot analysis of TRPC6 and nuclear NFATc1 expression. D1-D2, Quantification of the average intensity of NFATc1 and TRPC6 by Western blotting. E, Immunofluorescence staining of NFATc1 and TRPC6. The values are presented as the mean ± SD, *P < .05 vs low-glucose (LG); # P < .05 vs HG; @ P < .05 vs HG + TAC. n = 3. Real-time PCR, real-time polymerase chain reaction
Fig 4: Triptolide promoted osteoclastogenesis via inhibiting circ-0110634 (A–B) RT-qPCR was taken to examine several medicines effects on circ-0110634 expression in ASMSCs and its exosomes (C) Circ-0110634 expression was examined in different doses of triptolide applied in cells (D) The cellular morphology in ASMSCs exo/PBMCs treated with control or 7 ?nm triptolide or 14 ?nm triptolide was measured through TRAP staining (E) TRAP activity was examined in ASMSCs exo/PBMCs treated with control or 7 ?nm triptolide or 14 ?nm triptolide (F) Numbers of resorption pits were counted in ASMSCs exo/PBMCs treated with control or 7 ?nm triptolide or 14 ?nm triptolide (G–J) RT-qPCR along with western blot was taken to analyze the expression and protein levels of TRAP, NFATc1 and CTSK in ASMSCs exo/PBMCs treated with increasing doses of triptolide. **P ?< ?0.01, n. s. meant no significance.
Fig 5: Circ-0110634 inhibited osteoclastogenesis via regulating TRAF2 (A) TRAF2 expression and protein was measured in cells transfected with pcDNA3.1/TRAF2 (B) The cellular morphology in PBMCs transfected with pcDNA3.1 or pcDNA3.1/circ-0110634 or pcDNA3.1/circ-0110634+pcDNA3.1/TRAF2 was measured through TRAP staining (C) TRAP activity was examined in PBMCs transfected with pcDNA3.1 or pcDNA3.1/circ-0110634 or pcDNA3.1/circ-0110634+pcDNA3.1/TRAF2 (D) Numbers of resorption pits were counted in PBMCs transfected with pcDNA3.1 or pcDNA3.1/circ-0110634 or pcDNA3.1/circ-0110634+pcDNA3.1/TRAF2 (E–H) RT-qPCR along with western blot was taken to analyze the expression and protein levels of TRAP, NFATc1 and CTSK in PBMCs transfected with pcDNA3.1 or pcDNA3.1/circ-0110634 or pcDNA3.1/circ-0110634+pcDNA3.1/TRAF2. **P ?< ?0.01.
Supplier Page from Abcam for Anti-NFAT2 antibody